<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03963037</url>
  </required_header>
  <id_info>
    <org_study_id>20190130-1943</org_study_id>
    <nct_id>NCT03963037</nct_id>
  </id_info>
  <brief_title>Characterization of Two Novel Mutations in the Apob Gene</brief_title>
  <official_title>Characterization of Two Novel Truncating Mutations in the Apob Gene Leading to Hypobetalipoproteinemia: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University Innsbruck</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University Innsbruck</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pilot study has the target to evaluate the outcomes of two novel mutations in the gene of
      Apolipoprotein B (ApoB). ApoB is the main part of the low-density lipoprotein (LDL). LDL is
      the main transporter of cholesterol from the liver to the periphery. The two novel mutations
      lead to a heavily truncated Apolipoprotein B. Therefore the patients show severely decreased
      ApoB and LDL-Cholesterol levels. The acquired disease is known as &quot;Familial
      Hypobetalipoproteinemia&quot;. Beside the protection from cardiovascular disease due to decreased
      LDL-Cholesterol, patients tend to show elevated serum aminotransferases, fatty liver and
      occasional cases of cirrhosis and carcinoma.

      To elucidate the differences in lipoprotein assembly the investigators aim to characterize
      the changes due to the mutations in the patients. Family members not carrying the mutations
      are the control group. The assessment includes lipoprotein fractionation, MRI scans of the
      liver and a thorough assessment of medical history of all patients to look for potential side
      effects of the mutation.

      The only intervention needed for the study is to draw blood samples of every participant. The
      necessary positive vote from the ethics committee of the Medical University of Innsbruck is
      given.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2019</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Family-Based</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in lipoprotein profiles</measure>
    <time_frame>6 months</time_frame>
    <description>Lipoprotein profiles are measured via Fast Protein Liquid Chromatography in both groups and compared.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in amounts of liver fat</measure>
    <time_frame>12 months</time_frame>
    <description>Liver fat is non-invasive quantified by MRI scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Differences in HDL-efflux</measure>
    <time_frame>6 months</time_frame>
    <description>Compare the results between groups of HDL-efflux assays</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Familial Hypobetalipoproteinaemia - Heterozygous Form</condition>
  <condition>Low-LDL-syndrome</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>The family members of our two kindreds who carry the truncating mutation in the Apolipoprotein B gene.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>The family members of our two kindreds who are no carriers of the truncating mutation in the Apolipoprotein B gene.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood draw</intervention_name>
    <description>Draw venous blood for baseline blood parameters and plasma samples for lipoprotein fractionation.</description>
    <arm_group_label>Controls</arm_group_label>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The participants descend from two families. Each family carries a novel truncating mutation
        in the ApoB gene. The family members decided to participate in our pilotstudy to elucidate
        the changes caused by the mutations. Familial hypobetalipoproteinemia is a codominant
        disorder, so family members not carrying the mutations serve as control group.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Full legal age

          -  Written Informed Consent

          -  Diagnosed hypobetalipoproteinemia

          -  Exception of it are the controls

          -  Controls have to be family members

          -  Exclusion of a truncating mutation in the ApoB gene

        Exclusion Criteria:

          -  No diagnosed hypobetalipoproteinemia

          -  No truncating mutation in the Apo B gene

          -  Exception of it ar the controls
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Christoph Ebenbichler, MD, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Internal Medicine I, Medical University of Innsbruck, Austria</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clemens Engler, MD</last_name>
    <phone>+43 512 504 83659</phone>
    <email>clemens.engler@i-med.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christoph Ebenbichler, MD, Prof.</last_name>
    <email>christoph.ebenbichler@i-med.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <state>Tyrol</state>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Ebenbichler, MD, Prof.</last_name>
      <email>christoph.ebenbichler@i-med.ac.at</email>
    </contact>
    <investigator>
      <last_name>Christoph Ebenbichler, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clemens Engler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <reference>
    <citation>Welty FK. Hypobetalipoproteinemia and abetalipoproteinemia. Curr Opin Lipidol. 2014 Jun;25(3):161-8. doi: 10.1097/MOL.0000000000000072. Review.</citation>
    <PMID>24751931</PMID>
  </reference>
  <reference>
    <citation>Di Costanzo A, Di Leo E, Noto D, Cefal√π AB, Minicocci I, Polito L, D'Erasmo L, Cantisani V, Spina R, Tarugi P, Averna M, Arca M. Clinical and biochemical characteristics of individuals with low cholesterol syndromes: A comparison between familial hypobetalipoproteinemia and familial combined hypolipidemia. J Clin Lipidol. 2017 Sep - Oct;11(5):1234-1242. doi: 10.1016/j.jacl.2017.06.013. Epub 2017 Jun 24.</citation>
    <PMID>28733173</PMID>
  </reference>
  <reference>
    <citation>Schonfeld G. Familial hypobetalipoproteinemia: a review. J Lipid Res. 2003 May;44(5):878-83. Epub 2003 Mar 16. Review.</citation>
    <PMID>12639976</PMID>
  </reference>
  <reference>
    <citation>Hooper AJ, Heeks L, Robertson K, Champain D, Hua J, Song S, Parhofer KG, Barrett PH, van Bockxmeer FM, Burnett JR. Lipoprotein Metabolism in APOB L343V Familial Hypobetalipoproteinemia. J Clin Endocrinol Metab. 2015 Nov;100(11):E1484-90. doi: 10.1210/jc.2015-2731. Epub 2015 Aug 31.</citation>
    <PMID>26323024</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 22, 2019</study_first_submitted>
  <study_first_submitted_qc>May 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Apolipoprotein B</keyword>
  <keyword>Cholesterol</keyword>
  <keyword>Lipoprotein</keyword>
  <keyword>Metabolism</keyword>
  <keyword>Steatosis</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Hepatocellular Carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypobetalipoproteinemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

